{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T21:19:14Z","timestamp":1762377554964,"version":"3.40.3"},"reference-count":21,"publisher":"BMJ","issue":"1","funder":[{"name":"Retina.net e.V.","award":["Not Applicable."],"award-info":[{"award-number":["Not Applicable."]}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","award":["Not Applicable."],"award-info":[{"award-number":["Not Applicable."]}],"id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01GY1903"],"award-info":[{"award-number":["01GY1903"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Stiftung Auge der DOG","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"accepted":{"date-parts":[[2024,5,21]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>The Treatment exit Options For non-infectious Uveitis (TOFU) registry documents disease courses for non-anterior non-infectious uveitis entities with and without treatment to generate more evidence for clinical management recommendations including treatment exit strategies. In this article, we present the participants\u2019 baseline characteristics after the first 3 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>TOFU is an observational, prospective registry and recruits patients \u226518 years of age with non-anterior non-infectious uveitis with or without a history of previous disease-modifying antirheumatic drugs (DMARDs) treatment. The data are collected in the electronic data capture software REDCap and include ophthalmological and general medical history as well as clinical findings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between 24.10.2019 and 27.12.2022, 628 patients were enrolled at 25 clinical sites in Germany and Austria. Patients with intermediate uveitis were most frequently included (n=252; 40.1%) followed by posterior uveitis (181; 28.8%), panuveitis (n=154; 24.5%) and retinal vasculitis (n=41, 6.5%). At baseline, 39.6% were treated with systemic corticosteroids, 22.3% with conventional synthetic (cs) DMARDs, 20.5% with biological (b) DMARDs and 3.6% with other systemic treatments. Average best corrected visual acuity (BCVA) was 0.69 decimal. Patients with panuveitis had the worst BCVA with 0.63 decimal. Overall, only 8 patients (1.3%) suffered from severe visual impairment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Less than half of participants required DMARD treatment at baseline, with csDMARDs used more frequently than bDMARDs. The presence of severe visual impairment was low, mostly affecting patients with panuveitis. These findings are in line with comparable monocentric cross-sectional studies of tertiary uveitis centres in Germany and will allow us to generate generalisable evidence in TOFU.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjo-2023-324927","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T17:20:51Z","timestamp":1718040051000},"page":"27-33","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment exit options for non-infectious uveitis registry: participant characteristics at 3 years"],"prefix":"10.1136","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8593-4882","authenticated-orcid":false,"given":"David Julian","family":"Fink","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Dell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Heinz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian W M","family":"Wintergerst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"H\u00f6ller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moritz","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl Thomas","family":"Boden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5569-1473","authenticated-orcid":false,"given":"Uwe","family":"Pleyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert","family":"Reitsamer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph M E","family":"Deuter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tibor K","family":"Lohmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P","family":"Finger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,6,10]]},"reference":[{"key":"2025040105501286000_109.1.27.1","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2016.1196713"},{"key":"2025040105501286000_109.1.27.2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2010.194712"},{"key":"2025040105501286000_109.1.27.3","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.80.4.332"},{"key":"2025040105501286000_109.1.27.4","doi-asserted-by":"publisher","DOI":"10.5301\/ejo.5000278"},{"key":"2025040105501286000_109.1.27.5","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.80.9.844"},{"key":"2025040105501286000_109.1.27.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2003.06.014"},{"key":"2025040105501286000_109.1.27.7","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaophthalmol.2016.3229","article-title":"Prevalence of Noninfectious uveitis in the United States: A claims-based analysis","volume":"134","author":"Thorne","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"2025040105501286000_109.1.27.8","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1001\/jamaophthalmol.2013.4237","article-title":"Incidence and prevalence of uveitis: results from the Pacific ocular inflammation study","volume":"131","author":"Acharya","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"2025040105501286000_109.1.27.9","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.84.7.706"},{"key":"2025040105501286000_109.1.27.10","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-7-57","article-title":"Uveitis- a rare disease often associated with systemic diseases and Infections- a systematic review of 2619 patients","volume":"7","author":"Barisani-Asenbauer","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"2025040105501286000_109.1.27.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"2025040105501286000_109.1.27.12","doi-asserted-by":"crossref","DOI":"10.1016\/S0002-9394(01)00830-3","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"131","author":"Jabs","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"2025040105501286000_109.1.27.13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2016.06.007","article-title":"Immunosuppressive drug discontinuation in Noninfectious uveitis from real-life clinical practice: A survival analysis","volume":"169","author":"Ab\u00e1solo","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"2025040105501286000_109.1.27.14","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.ophtha.2013.11.032","article-title":"Outcomes of changing immunosuppressive therapy after treatment failure in patients with Noninfectious uveitis","volume":"121","author":"Joshi","year":"2014","journal-title":"Ophthalmology"},{"key":"2025040105501286000_109.1.27.15","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1007\/s10792-021-01763-8","article-title":"New Pharmacotherapy options for Noninfectious posterior uveitis","volume":"41","author":"Pleyer","year":"2021","journal-title":"Int Ophthalmol"},{"key":"2025040105501286000_109.1.27.16","unstructured":"German society of Ophthalmology (Deutsche Ophthalmologische Gesellschaft, DOG), German Professional Association of Ophthalmologists (Berufsverband der Augen\u00e4rzte Deutschlands e.V.) . Statement of the DOG and the BVA No 24b: Non-Infectious Posterior Uveitis [Leitlinie Nr 24b Der DOG Und BVA: Nichtinfekti\u00f6se Uveitis Posterior] Ophthalmologe. 1122-34. 2017. Available: https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-017-0582-z.pdf"},{"key":"2025040105501286000_109.1.27.17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/09286586.2021.1887285","article-title":"Treatment exit options for non-infectious uveitis (TOFU): study protocol for a prospective clinical Registry","volume":"29","author":"Li","year":"2022","journal-title":"Ophthalmic Epidemiol"},{"key":"2025040105501286000_109.1.27.18","first-page":"S39","article-title":"The treatment exit options for uveitis (TOFU) Registry: involving patients in the generation of evidence [Das Treatment Exit Options for Uveitis (TOFU) Register: Einbindung von Patienten in die Evidenzgenerierung]","volume":"83","author":"Li","year":"2021","journal-title":"Gesundhwes"},{"key":"2025040105501286000_109.1.27.19","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2014.1002567"},{"key":"2025040105501286000_109.1.27.20","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080102"},{"key":"2025040105501286000_109.1.27.21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s12348-011-0047-5","article-title":"Corticosteroid-sparing therapy: practice patterns among uveitis specialists","volume":"2","author":"Esterberg","year":"2012","journal-title":"J Ophthalmic Inflamm Infect"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjo-2023-324927","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T21:02:10Z","timestamp":1743541330000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjo-2023-324927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,10]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,17]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/bjo-2023-324927"],"URL":"https:\/\/doi.org\/10.1136\/bjo-2023-324927","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"type":"print","value":"0007-1161"},{"type":"electronic","value":"1468-2079"}],"subject":[],"published":{"date-parts":[[2024,6,10]]}}}